APO-1 (APOSECTM): Injectable formulation for the improvement of cardiac function in chronic myocardial ischemia
Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 (APOSECTM).
APO-2 (APOSECTM): Topical formulation for the treatment of diabetic foot ulcers and other chronic wounds
Aposcience AG will initiate a program to demonstrate safety and efficacy in this important indication with very large unmet medical need. The program consists of a phase I study in healthy volunteers, followed by a phase IIa study in a selected patient population. This program is designed to translate the extremely promising data from animal models into clinical practice.
Marsyas I, a prospective, single-center, randomized, double-blinded, placebo controlled, dose finding clinical phase I study in the indication wound healing (ClinicalTrials.gov Identifier: NCT02284360) was initiated on 23 October 2014 at the Department of Clinical Pharmacology of the Medical University of Vienna. The study was completed on 5 February 2016 (date of study Report). A Synopsis can be found here: Study Report – Synopsis PDF Download
Marsyas II, a randomized, placebo-controlled, double-blind study to evaluate safety and dosedependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulce (EudraCT number: 2018-001653-27, ClinicalTrials.gov Identifier: NCT04277598) was initiated in October 2020 and could be finished in December 2023. More information can be found here and at trialsjournal.biomedcentral.com.